Abstracts Archive - Page 194 of 2425 - ACR Meeting Abstracts

Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…
Abstract Number: 0435 • ACR Convergence 2023
Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data
Stephanie Song¹, Bryant England², Brian Sauer³, Michael George⁴, Beth Wallace⁵, Grant Cannon⁶, Ted R Mikuls⁷ and Joshua Baker⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE), and cancer associated with Janus kinase inhibitors (JAKi). The aim of this study…
Abstract Number: 0439 • ACR Convergence 2023
Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)
JACQUES MOREL¹, Olivier Brocq², Cécile Gaujoux Viala³, Arnaud Constantin⁴, Slim Lassoued⁵, Emanuelle Dernis⁶, Christophe Richez⁷, Cedric Lukas⁸, Claire Daien⁹ and Claire Duflos¹⁰, ¹Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ²Hospital of Princesse Grâce de Monaco, Monaco, Monaco, ³IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁴Teaching hospital Purpan, and University of Paul Sabatier, Toulouse, France, ⁵Hospital of Jean-Rougié, Cahors, France, ⁶CH Le Mans, Le Mans, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸CHU Montpellier, Montpellier, France, ⁹University Hospital, Montpellier, France, ¹⁰CHU and University of Montpellier, Montpellier, France
Background/Purpose: To prevent infections, EULAR recommends to vaccinate RA patients against streptococcal pneumoniae. PCV13 is a T- cell dependent vaccine whereas PPSV23 induces a T-independent…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…
Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Marc Blanchard¹, Pedro Ming Azevedo², Tiffany Prétat², Cinja Koller² and Thomas Hügle³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²Lausanne University Hospital, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…
Abstract Number: 0426 • ACR Convergence 2023
The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Tomokazu Choshi¹, Kenji Mamoto¹, Yutaro Yamada¹, Tadashi Okano¹, Shohei Anno², Kazuki Orita², Takahiro Iida³, Masahiro Tada⁴, Kentaro Inui⁵, Tatsuya Koike⁶ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Koryokai Hospital, Osaka, Japan, ⁴Osaka City General Hospital, Osaka, Japan, ⁵Saiseikai Nakatsu Hospital, Osaka, Japan, ⁶Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi…
Abstract Number: 0385 • ACR Convergence 2023
Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort
Laura BRICMAN¹, clement triaille², Francesco Natalucci³, Emilie Sapart², Tatiana Sokolova⁴, Aleksandra AVRAMOVSKA¹, Thomas KIRCHGESNER⁵ and Patrick Durez², ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³UCLouvain University, Sermoneta, Italy, ⁴Université Catholique de Louvain, Brussels, Belgium, ⁵Rheumatology, Cliniques Universitaires Saint-Luc Département d'imagerie médicale – Université catholique de Louvain (UCLouvain), Brussels, Belgium
Background/Purpose: ERA is considered to be a systemic disorder, but the role of local factors in driving synovial inflammation is increasingly being recognized. These joint-specific…
Abstract Number: 0396 • ACR Convergence 2023
Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study
Hsin-Hua Chen¹ and DER-YUAN CHEN², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Center of Rheumatology, China Medical University Hospital, Taichung, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic destructive arthritis and extra-articular involvement. Prior studies showed patients with RA had…
Abstract Number: 0321 • ACR Convergence 2023
Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis
Koushik Sangaraju¹, Radu Grovu², Michael Kwark², Elizabeth Cohen², Amira Hassan³ and Anastasia Slobodnick², ¹Staten Island University Hospital - Northwell Health, Staten Island, NY, ²Northwell Health, Staten Island, NY, ³Northwell Health, Brooklyn, NY
Background/Purpose: Osteoarthritis and rheumatoid arthritis cause significant joint replacement morbidity. Proton pump inhibitors (PPIs) may contribute to chronic inflammation and joint degeneration due to side…
Abstract Number: 0338 • ACR Convergence 2023
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey
Diego Benavent¹, Marco Fornaro², Florenzo Iannone³, Lorenzo Cavagna⁴, Masataka Kuwana⁵, Naveen R⁶, Vishwesh Agarwal⁷, Jessica Day⁸, Mrudula Joshi⁹, Sreoshy Saha¹⁰, Kshitij Jagtap¹¹, Wanruchada Katchamart¹², Phonpen Akarawatcharangura Goo¹³, Binit Vaidya¹⁴, Tsvetelina Velikova¹⁵, Parikshit Sen¹⁶, Samuel Shinjo¹⁷, Ai Lyn Tan¹⁸, Nelly Ziade¹⁹, Marcin Milchert²⁰, Abraham Edgar Gracia-Ramos²¹, Carlo Caballero²², Hector Chinoy²³, Vikas Agarwal⁶, Rohit Aggarwal²⁴, Latika Gupta²⁵ and Vincenzo Venerito²⁶, ¹Hospital la Paz, Madrid, Spain, ²University of Bari, Grottaglie, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁷Mahatma Gandhi Missions Medical College, Lucknow, India, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹²Mahidol University, Bangkok, Thailand, ¹³Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ¹⁴National Center for Rheumatic Diseases (NCRD), Ratopul, Kathmandu, Nepal., Kathmandu, India, ¹⁵Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁶Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁷Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Saint-Joseph University, Beirut, Lebanon, ²⁰Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²¹Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ²²Universidad del Norte, Barranquilla, Colombia, ²³The University of Manchester, Sale, United Kingdom, ²⁴University of Pittsburgh, Pittsburgh, PA, ²⁵Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁶Rheumatology Department, Università degli Studi di Bari, Bari, Italy
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including either Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS), are some of the most commonly diagnosed autoimmune rheumatic…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 0399 • ACR Convergence 2023
Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory
Simone Perniola¹, Jessica Murillo-Saich², Barbara Tolusso³, Clara Di Mario³, Marco Gessi⁴, Dario Bruno⁵, Luca Petricca⁶, Maria Rita Gigante⁶, Elisa Gremese⁵, Monica Guma⁷ and Stefano Alivernini⁸, ¹Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, ⁶Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷University of California San Diego, La Jolla, CA, ⁸Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
Abstract Number: 0406 • ACR Convergence 2023
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study
Violetta Dubovyk¹, Gerdur Maria Grondal², Bjorn Gudbjornsson³, Espen A Haavardsholm⁴, Marte Schrumpf Heiberg⁴, Merete Hetland⁵, Kim Hørslev-Petersen⁶, Meliha Kapetanovic⁷, Alf Kastbom⁸, John Lampa⁹, Kristina Lend¹⁰, Dan Nordstrom¹¹, Michael Nurmohamed¹², Milad Rizk¹³, Annika Söderbergh¹⁴, Till Uhlig¹⁵, Mikkel Østergaard¹⁶, Ronald van Vollenhoven¹², Anna Rudin¹⁷ and Cristina Maglio¹⁸, ¹University of Gothenburg, Gothenburg, Sweden, ²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Lund University and Skåne University Hospital, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Stockholm County, Hãsselby, Sweden, ¹⁰Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Västmanlands Hospital Västerås, Västerås, Sweden, ¹⁴Örebro University Hospital, Örebro, Sweden, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ¹⁸Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
Abstract Number: 0419 • ACR Convergence 2023
No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors
Romy Hansildaar¹, Reinder Raadsen¹, Maaike Heslinga² and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-fold higher risk of venous thromboembolism (VTE) compared with the general population. The immune system and hemostatic…
Abstract Number: 0414 • ACR Convergence 2023
Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe
Douglas White¹, Aditi Kadakia², Oliver Howell³, Sander Strengholt⁴, Emily Goddard³, Sophie Barlow³ and Tsutomu Takeuchi⁵, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].